Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent prior to study-specific screening procedures
Life expectancy of ≥ 60 days
Eastern Cooperative Group (ECOG) performance status ≤ 2
Refractory AML with confirmed initial diagnosis of de novo AML (excluding APL) - OR- Refractory AML with confirmed initial diagnosis of AML (excluding APL) secondary to AHD or MDS with either condition precedent to AML (MDS/AHD)
Negative serum pregnancy test (within 7 days of first dose)
Negative urine pregnancy test immediately prior to first dose
You may not be if
Known HIV
Psychiatric disorder that interfered with ability to understand the study and give informed consent, and/or would impact study participation or follow-up
Concurrent use of medications that might prolong the QT interval or of inducing Torsade de Pointes
Female patients who were pregnant or breast-feeding or patients of childbearing potential who were not willing to use a double barrier method of contraception during the study and for 3 months following the last dose of study drug.
Male patients whose sexual partner(s) were women of childbearing potential who were not willing to use a double method of contraception, one of which included a condom, during the study and for 3 months after the end of treatment
Patient unable to swallow capsules
Patients with impaired gastrointestinal systems which might cause interference with digesting and absorbing panobinostat
Clareo Health | Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
